» Articles » PMID: 30881993

Predicting MicroRNA Target Genes and Identifying Hub Genes in IIA Stage Colon Cancer Patients Using Bioinformatics Analysis

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2019 Mar 19
PMID 30881993
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Colon cancer is a heterogeneous disease, differing in clinical symptoms, epigenetics, and prognosis for each individual patient. Identifying the core genes is important for early diagnoses and it provides a more precise method for treating colon cancer.

Materials And Methods: In this study, we wanted to pinpoint these core genes so we obtained GSE101502 microRNA profiles from the GEO database, which resulted in 17 differential expressed microRNAs that were identified by GEO2R analysis. Then, 875 upregulated and 2920 downregulated target genes were predicted by FunRich. GO and KEGG pathway were used to do enrich analysis.

Results: GO analysis indicated that upregulated genes were significantly enriched in the regulation of cell communication and signaling and in nervous system development, while the downregulated genes were significantly enriched in nervous system development and regulation of transcription from the RNA polymerase II promoter. KEGG pathway analysis suggested that the upregulated genes were enriched in axon guidance, MAPK signaling pathway, and endocytosis, while the downregulated genes existed in pathways in cancer, focal adhesion, and PI3K-Akt signaling pathway. The top four molecules including 82 hub genes were identified from the PPI network and involved in endocytosis, spliceosome, TGF-beta signaling pathway, and lysosome. Finally, NUDT21, GNB1, CLINT1, and COL1A2 core gene were selected due to their correlation with the prognosis of IIA stage colon cancer.

Conclusion: this study suggested that NUDT21, GNB1, CLINT1, and COL1A2 might be the core genes for colon cancer that play an important role in the development and prognosis of IIA stage colon cancer.

Citing Articles

ceRNA network-regulated COL1A2 high expression correlates with poor prognosis and immune infiltration in colon adenocarcinoma.

Yuan X, He Y, Wang W Sci Rep. 2023; 13(1):16932.

PMID: 37805556 PMC: 10560230. DOI: 10.1038/s41598-023-43507-x.


Novel diagnostic and prognostic biomarkers of colorectal cancer: Capable to overcome the heterogeneity-specific barrier and valid for global applications.

Hameed Y, Usman M, Liang S, Ejaz S PLoS One. 2021; 16(9):e0256020.

PMID: 34473751 PMC: 8412268. DOI: 10.1371/journal.pone.0256020.


Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry.

Engqvist H, Parris T, Kovacs A, Ronnerman E, Sundfeldt K, Karlsson P Front Oncol. 2020; 10:162.

PMID: 32133296 PMC: 7040170. DOI: 10.3389/fonc.2020.00162.

References
1.
Toyota M, Ahuja N, Herman J, Baylin S, Issa J . CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999; 96(15):8681-6. PMC: 17576. DOI: 10.1073/pnas.96.15.8681. View

2.
Shannon P, Markiel A, Ozier O, Baliga N, Wang J, Ramage D . Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504. PMC: 403769. DOI: 10.1101/gr.1239303. View

3.
Apweiler R, Bairoch A, Wu C, Barker W, Boeckmann B, Ferro S . UniProt: the Universal Protein knowledgebase. Nucleic Acids Res. 2003; 32(Database issue):D115-9. PMC: 308865. DOI: 10.1093/nar/gkh131. View

4.
Fang J, Richardson B . The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005; 6(5):322-7. DOI: 10.1016/S1470-2045(05)70168-6. View

5.
Farazi T, Juranek S, Tuschl T . The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members. Development. 2008; 135(7):1201-14. DOI: 10.1242/dev.005629. View